Cancer clinical trials in the region Occitanie
385 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Endometrial cancer
#NCT04585750
#2023-504251-27-00
Phase 2 cohorte de patients atteints d'un cancer de l'endomètre
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
KRAS G12C
KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2
Lung cancer
Colon cancer
Rectal cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Cervical / Vulvar / Vaginal cancer
#NCT07169734
#2025-521441-24-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Cervical cancer
Required histologic sub types
Squamous NSCLC
Adenocarcinoma
Intrahepatic cholangiocarcinoma
Urothelial carcinoma
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
4 recruiting sites
Alentis Therapeutics AG
Phase 1 / Phase 2
Lung cancer
Stomach and esophageal cancer
Head and neck cancer
Cervical / Vulvar / Vaginal cancer
#NCT06747585
#2024-515459-39-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Esophagus
Cervical cancer
Required histologic sub types
Squamous NSCLC
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Alentis Therapeutics AG
Phase 1 / Phase 2
Lung cancer
#NCT06043817
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
EGFR
HER2
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2
Breast cancer
#NCT05768139
#2023-000442-41
Cohortes combinaison extension de dose cancer du sein RH+
Required HER2 statuses
HER2 Negative
HER2 Low
Required HR statuses
HR Positive
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Eli Lilly et compagnie
Phase 1 / Phase 2
Acute leukemia
#NCT04811560
Phase 2
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Treated / Controled
Required genetic anomalies
KMT2A
NPM1
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
11 recruiting sites
Janssen
Phase 1 / Phase 2
Acute leukemia
#NCT04811560
Phase 1
Required central nervous system lesions
None
Treated / Controled
Required genetic anomalies
Other mutation
KMT2A
NPM1
NUP214
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
11 recruiting sites
Janssen
Phase 1 / Phase 2
Lymphoma
#NCT05475925
Escalade de dose (partie A) et Extension de dose (partie B) cohorte B2
Required histologic types
T cell lymphoma
Required histologic sub types
Peripheral T cell lymphoma
Cutaneous T-cell lymphoma
Required disease stage
Disseminated (stage III and IV)
Required central nervous system lesions
None
Treated / Controled
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Dren Bio
Phase 1 / Phase 2
Breast cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
#NCT05118789
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ROS-1
Required number of previous lines of therapy for current stage of disease
1
4 recruiting sites
Nuvalent Inc.
Phase 1 / Phase 2
Lung cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Head and neck cancer
#NCT06923761
#2023-504845-30-00
Module 2 Cohorte 3 Tumeurs solides avec un TMB médian modéré à élevé
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Stomach
Oesogastric junction
Esophagus
Invasive bladder cancer
Oral cavity
Nasopharynx
Oropharynx
Hypopharynx
Larynx
Nasal cavities and sinuses
Required histologic sub types
Adenocarcinoma
Squamous cell carcinoma
Urothelial carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics